Maitreyee Bhattacharyya

Maitreyee Bhattacharyya

Auto-generated profile, based on publicly available information

Maitreyee Bhattacharyya

Department of Molecular Biology, #Institute of Hematology and Transfusion Medicine, Medical College Hospital Kolkata, West Bengal, India

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JSJyoti Shaw
Jyoti Shaw
ACAyan Chakraborty
Ayan Chakraborty
ANArijit Nag
Arijit Nag
ACArnab Chattopadyay
Arnab Chattopadyay
ADAnjan Dasgupta
Anjan Dasgupta
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya

17 October 2011 in Hemoglobin
Verified
Journal Article
Closed access
TDTuphan Kanti Dolai
Tuphan Kanti Dolai
SDShyamali Dutta
Shyamali Dutta
MBMaitree Bhattacharyya
Maitree Bhattacharyya
MGMalay Kumar Ghosh
Malay Kumar Ghosh
India is in the thalassemia belt of the world. Both α- and β-thalassemia (α- and β-thal) are found in West Bengal, a state in the eastern part of India. There was no systematic large published study to investigate the prevalence rates of different hemoglobinopathies in West Bengal. This study was conducted in school and college students, newly married couples and pregnant women after proper counseling in the rural areas of five districts of West Bengal state in eastern India. Thalassemia testing was done using high performance liquid chromatography (HPLC). A total of 35,413 individuals were screened for hemoglobinopathies. β-Thalassemia trait was found in 10.38%, Hb E [β26(B8)Glu→Lys] trait in 4.30%, sickle cell trait in 1.12%, borderline Hb A2 value 0.73%, low Hb A2 0.68% and Hb D trait 0.37%. This is the first study that addresses the prevalence of different hemoglobinopathies in rural areas of West Bengal. The prevalence of β-thal trait is higher in West Bengal than other parts of India. This data is likely to be helpful in planning screening programs in rural areas of West Bengal, India.

9 May 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SKSiddhesh Arun Kalantri
Siddhesh Arun Kalantri
RRRudra Ray
Rudra Ray
ACArnab Chattopadhyay
Arnab Chattopadhyay
SBSunistha Bhattacharjee
Sunistha Bhattacharjee
ABAnkita Biswas
Ankita Biswas
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya

22 February 2014 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
PMPrakas Kumar Mandal
Prakas Kumar Mandal
TDTuphan Kanti Dolai
Tuphan Kanti Dolai
BBBasab Bagchi
Basab Bagchi
MGMalay Kumar Ghosh
Malay Kumar Ghosh
SBSudipta Bose
Sudipta Bose
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya

1 June 2004 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya
GMGovind Makharia
Govind Makharia
MKM. Kannan
M. Kannan
RAR.P.H. Ahmed
R.P.H. Ahmed
PGP.K. Gupta
P.K. Gupta
RSRenu Saxena
Renu Saxena
We studied 57 patients with Budd-Chiari syndrome (BCS) and 48 with portal vein thrombosis (PVT) for underlying inherited prothrombotic defects such as protein C, protein S, and antithrombin III deficiencies. Genetic mutations for factor V Leiden, prothrombin gene 20210A, and methyltetrahydrofolate reductase (MTHFR) C677T were studied in 29 patients in each group. Inherited prothrombotic defects were detected in 16 (28%) of 57 patients with BCS and 7 (15%) of 48 patients with PVT. Factor V Leiden mutation was the most common prothrombotic defect in BCS (5/29 [17%]) followed by protein C deficiency (7/57 [12%]) and protein S deficiency (4/57 [7%]), whereas in PVT, protein C deficiency was the most common inherited prothrombotic defect (4/48 [8%]) followed by protein S deficiency (2/48 [4%]). The factor V Leiden mutation was detected in only 1 (3%) of 29 cases of PVT. The heterozygous MTHFR C677T mutation was detected in 7 (24%) of 29 patients with BCS and 6 (21%) of 29 patients with PVT. Antithrombin III deficiency, homozygous MTHFR C677T mutation, and prothrombin G20210A mutation were not detected in any patients.

1 October 2007 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
MBMaitreyee Bhattacharyya
Maitreyee Bhattacharyya
MKMeganathan Kannan
Meganathan Kannan
VCVed P. Chaudhry
Ved P. Chaudhry
MMM. Mahapatra
M. Mahapatra
HPH. Pati
H. Pati
RSRenu Saxena
Renu Saxena
Fifty-three patients of thalassemia intermedia and 40 controls were studied for clinical evidence of thrombosis and laboratory evidence of hypercoagulable state. Thrombotic episodes were detected in 5 (9.4%) patients. Two of these 5 patients with thrombosis were splenectomized. Laboratory evaluation showed presence of thrombocytosis in 8 (15%), 5 of these were splenectomized. Platelet hyperaggregation was detected in 12 (22.2%) patients. Although rate of aggregation was slow in 7 (13.2%) patients, degree of aggregation was normal in these 7 patients and platelet hypoaggregation was not detected in any patient. Level of coagulation inhibitors protein C and protein S, and antithrombin III were decreased in 31 (58.4%) patients. There was no correlation between low level of protein C and protein S with hepatic dysfunction and iron overload. Antithrombin III level was decreased only in 8 (15%) patients. There was a statistically significant association between the lower level of this inhibitor and hepatic dysfunction. In conclusion, this study provides evidence for the existence of a chronic hypercoagulable state in patients with β thalassemia intermedia, and suggests that expression of a procoagulant surface by thalassemia intermedia red blood cells may be the major underlying factor giving rise to platelet and coagulation inhibitor abnormalities in these patients. These alterations are not related to iron overload or hepatic dysfunction.